Oksana Shevchuk

Prof. Dr. Oksana Shevchuk

I. Horbachevsky Ternopil National Medical University
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Medicine
Verified
Journal Article
Open access
MNMahin Nomali
Mahin Nomali
MHMohammad Eghbal Heidari
Mohammad Eghbal Heidari
AAAryan Ayati
Aryan Ayati
ATAmirhossein Tayebi
Amirhossein Tayebi
OSOksana Shevchuk
Oksana Shevchuk
HGHadis Gerami
Hadis Gerami
Backgrounds: Omega-3 supplements are endorsed for heart failure (HF) patients to reduce hospitalizations and mortality, offering anti-inflammatory and cardioprotective benefits. Methods: A comprehensive search was conducted in various databases until November 2022. Eligible studies included clinical trials on patients with HF. Data extraction covered study details, omega-3 specifics, outcomes, and limitations. The JADAD scale was used to assess the risk of bias in randomized controlled trials. Results: The review process involved 572 records from database searches, resulting in 19 studies after eliminating duplicates and screening. These studies assessed the impact of omega-3 on various clinical outcomes, such as mortality, hospitalization, cardiac function, and quality of life. Studied duration varied from weeks to years. Omega-3 supplementation demonstrated potential benefits such as improved heart function, reduced inflammation, and decreased risk of cardiovascular events. Conclusion: Omega-3 supplementation could benefit heart disease treatment, potentially reducing therapy duration and improving outcomes. Starting omega-3 supplementation for HF patients seems favorable.

8 September 2023 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
Krzysztof KorzeniewskiKrzysztof Korzeniewski
Krzysztof Korzeniewski
MSMariia Shkilna
Mariia Shkilna
MHMariana Huk
Mariana Huk
OSOksana Shevchuk
Oksana Shevchuk
MMMałgorzata Marchelek-Myśliwiec
Małgorzata Marchelek-Myśliwiec
The armed aggression of the Russian Federation against Ukraine which started on 24 February 2022 resulted in a massive influx of war refugees from Ukraine. Ukrainian citizens crossed the international borders to flee from the war and apply for an asylum either in Poland or in other EU countries. As many as 115 000 Ukrainians crossed the Polish border in the first 3 days of the Russian invasion. The number grew to 2.3 million over the next 5 weeks. Until July 2023, a total of 13.8 million war refugees crossed the Ukrainian–Polish border on foot, by car or by train. The refugees were predominantly women and children (only ~3% of the war refugees in the given period were men). Until July 2023, 12 million Ukrainians returned from Poland to Ukraine. 1 At mid-2023 there are ˃3 million Ukrainian citizens living in Poland, including at least 1.3 million economic migrants who had arrived before Russian invasion and 1.8 million war refugees who crossed the Polish border after February 2022. The population in Poland, including 37.5 million Polish nationals, has exceeded 40 million people for the first time in history. 1 According to the United Nations Refugee Agency, the estimated number of Ukrainian war refugees in the world is 6.3 million as of June 2023, which is the largest migration flow since World War 2 (by comparison, 1.83 million refugees arrived in Europe, mainly from Africa and Asia, during the European migrant crisis in 2015). 2

14 October 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KKKateryna Kozak
Kateryna Kozak
HPHalyna Pavlyshyn
Halyna Pavlyshyn
Oleksandr KamyshnyiOleksandr Kamyshnyi
Oleksandr Kamyshnyi
OSOksana Shevchuk
Oksana Shevchuk
MKMykhaylo Korda
Mykhaylo Korda
SVSandor George Vari
Sandor George Vari
Coronavirus disease (COVID-19) and its outcomes remain one of the most challenging problems today. COVID-19 in children could be asymptomatic, but can result in a fatal outcome; therefore, predictions of the disease severity are important. The goal was to investigate the human genetic factors that could be associated with COVID-19 severity in children. Single-nucleotide polymorphisms of the following genes were studied: ACE2 (rs2074192), IFNAR2 (rs2236757), TYK2 (rs2304256), OAS1 (rs10774671), OAS3 (rs10735079), CD40 (rs4813003), FCGR2A (rs1801274) and CASP3 (rs113420705). In the case–control study were 30 children with mild or moderate course of the disease; 30 with severe COVID-19 symptoms and multisystem inflammatory syndrome in children (MIS-C) and 15 who were healthy, and who did not have SARS-CoV-2 (PCR negative, Ig G negative). The study revealed that ACE2 rs2074192 (allele T), IFNAR2 rs2236757 (allele A), OAS1 rs10774671 (allele A), CD40 rs4813003 (allele C), CASP3 rs113420705 (allele C) and male sex contribute to severe COVID-19 course and MIS-C in 85.6% of cases. The World Health Organization reported that new SARS-CoV-2 variants may cause previously unseen symptoms in children. Although the study has limitations due to cohort size, the findings can help provide a better understanding of SARS-CoV-2 infection and proactive pediatric patient management.

2 September 2019 in Medicina
Verified
Journal Article
Open access
PDF file
OSOksana Shevchuk
Oksana Shevchuk
ESElisaveta Snezhkova
Elisaveta Snezhkova
VSVeronika Sarnatskaya
Veronika Sarnatskaya
VMVictor Mikhailenko
Victor Mikhailenko
AGAlexei Glavin
Alexei Glavin
VNVolodymyr Nikolaev
Volodymyr Nikolaev
Background and Objectives: Side effects of anti-cancer drugs are usually accompanied by oxidative stress, including myelotoxicity. We evaluated the potential of oral highly activated micro-/macroporous carbon adsorbents (bulk density of 0.16 g/cm3, surface area calculation by Brunauer–Emmett–Teller model (SBET) > 2200 m2/g, derived from proprietary phenolic resin beads) to alleviate oxidative stress and myelotoxicity in rats. Materials and Methods: A single injection of cytostatic melphalan (L-PAM) at a dose of 4 mg/kg was used for modelling. Two forms of activated carbon were used: AC1—primary beads with the particle size range of 125–250 µm, and AC2—micronized AC1 with a mean particle size of ~1 µm. We measured haematological parameters white blood cells, red blood cells, platelet count, and haemoglobin level. Oxidative stress intensity was evaluated using the following markers: total levels of reactive oxygen species (ROS) in blood plasma; catalase activity (CAT) and pro-oxidant/antioxidant ratio in blood haemolysate samples; level of reduced glutathione (GSH) in liver tissues; oxidative modification of proteins, OPM (APHD, aldehyde–dinitrophenylhydrazone derivatives and KPHD, ketone dinitrophenylhydrazone derivatives) and malonic dialdehyde (MDA) in blood plasma and liver samples. Results: AC2 administration promoted significant myeloprotective effect: 1.5-fold increase in leukocytes, 2-fold in neutrophils, 1.5-fold in lymphocytes, and 1.23-fold in platelet count compared to the experimental Melphalan Group. At the same time, AC1 administration resulted in a slight increase in haematological parameters. Both ACs positively corrected important, but diverse, components of oxidative stress. They significantly reduced oxidative modification of blood and liver proteins (especially the AC1 form), normalized the level of reduced glutathione, pro-oxidant/antioxidant ratio and other markers. For some markers, such as ROS production in blood plasma, the use of enterosorbents resulted in non-significant a shift towards normal parameters. Conclusions: Oral activated carbon adsorbents reduce oxidative stress intensity and myelotoxicity; they can be promising means to combat the adverse effects of chemotherapy in clinical practice.

Verified
Journal Article
Open access
PDF file
OSOksana Shevchuk
Oksana Shevchuk
AVAnastasiia Voitovych
Anastasiia Voitovych
Svitlana PaliiSvitlana Palii
Svitlana Palii
YIYana Ivankiv
Yana Ivankiv
KKKateryna Kozak
Kateryna Kozak
SVSandor George Vari
Sandor George Vari
ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.

3 August 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
IHIvanna Hudan-Tsilo
Ivanna Hudan-Tsilo
OTOleksandr Tokarskyy
Oleksandr Tokarskyy
OSOksana Shevchuk
Oksana Shevchuk
MKMykhaylo Korda
Mykhaylo Korda
The study was performed with an aim to investigate the efficiency of two treatment options in experimental nickel-induced contact dermatitis (CT), with either betamethasone or chitosan cross-linked...